Does Ketamine Have Anti-Suicidal Properties? Current Status and Future Directions
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Ketamine, a widely used anesthetic agent, is currently being investigated as a novel therapeutic for depression and suicidality. Ketamine has garnered substantial attention from researchers, clinicians, media outlets, and patients alike, but numerous questions remain. One of the compelling features of ketamine is the rapidity of its antidepressant effects, which peak just 24 h after infusion, setting it apart from other existing treatments. Ketamine’s rapid time course has inspired research efforts to explore its potential as a life-saving therapy for patients at imminent risk of suicide. In this article, we review current evidence supporting the rapid effects of ketamine on suicidal ideation in the context of unipolar and bipolar depression. We then discuss several future directions that are necessary before ketamine can be considered a viable treatment option for suicidality in clinical settings. These include: testing for a specific anti-suicidal effect—separate from overall antidepressant effects—to ascertain whether ketamine might hold promise for a broader class of suicidal patients; ensuring that acute benefits of ketamine can be prolonged over a clinically meaningful timeframe; and developing a better understanding of the mechanisms by which ketamine might reduce suicide risk. Such efforts will enable the field to more accurately assess the potential of ketamine, as well as its limitations, allowing for appropriate placement within the context of comprehensive clinical care for suicide prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Nock, M. K., Borges, G., Bromet, E. J., Cha, C. B., Kessler, R. C., & Lee, S. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn002 · Cited by 2,897
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 2×
“, [3, 4]), has sparked interest in its potential as an anti-suicide treatment.”
Self-citationRelationship between hopelessness and ultimate suicide: a replication with psychiatric outpatients
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.2.190 · Cited by 1,120
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 1×
“5 mg/kg over 40 min) or saline infusion in a double-blind, cross-over design [21].”
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 1×
“after ketamine treatment [20, 28, 29], consistent with enduring antidepressant-like effects observed in rats following repeated administrations [30].”
Self-citationSafety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Self-citationNock, M. K., & Kessler, R. C. (2006) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.115.3.616 · Cited by 680 · cited 1×
“Suicide risk is elevated in a wide range of diagnostic groups [23] and exhibits unique genetic variance that can be inherited separately from mood disorder risk [24].”
Measuring the Suicidal Mind: Implicit Cognition Predicts Suicidal Behavior
Nock, M. K., Park, J. M., Finn, C. T., Deliberto, T. L., Dour, H. J., & Banaji, M. R. (2010) · Psychological Science · doi:10.1177/0956797610364762 · Cited by 624 · cited 1×
“plicit suicide-related cognition, assessed by the IAT, is also a strong prospective predictor of future suicide attempts, outperforming a variety of demographic and clinical indicators [44].”
Suicide Risk in Relation to Psychiatric Hospitalization: Evidence Based on Longitudinal Registers
Qin, P., & Nordentoft, M. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.427 · Cited by 620 · cited 1×
“[11].”
Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600 · cited 16×
“The first published report examining ketamine’s effects on suicidality was an open-label trial of intravenous ketamine in a sample of 26 patients with treatment-resistant major depression (TRD) [12].”
InfluentialSelf-citationDiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564 · cited 2×
“Similar results were obtained in a sample of 33 TRD patients following a single infusion [14] at the same dose as in the Price et al.”
Harmer, C. J., Goodwin, G. M., & Cowen, P. J. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.051193 · Cited by 542 · cited 1×
“A similar model has recently been proposed for the serotonergic antidepressants, wherein acute drug effects on performance-based measures of cognitive-affective processing are posited to explain downstream therapeutic benefits [45].”
Suicide Ideation at Its Worst Point: A Predictor of Eventual Suicide in Psychiatric Outpatients
Beck, A. T., Brown, G. K., Steer, R. A., Dahlsgaard, K. K., & Grisham, J. R. (1999) · Suicide and Life-Threatening Behavior · doi:10.1111/j.1943-278x.1999.tb00758.x · Cited by 475 · cited 2×
“However, current SI is a relatively imprecise proxy for overt suicidal behaviors like suicide completion [26].”
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-053013-062946 · Cited by 422 · cited 1×
“Hypothesized mechanisms have been reviewed elsewhere [33], and include alterations in glutamatergic and dopaminergic function and neuroplasticity (e.”
Ketamine for Depression: Where Do We Go from Here?
aan het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.003 · Cited by 418 · cited 1×
“Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist that has shown promise as a novel therapeutic for unipolar and bipolar depression [1, 2].”
Self-citationConnecting inflammation with glutamate agonism in suicidality
Erhardt, S., Lim, C. K., Linderholm, K. R., Janelidze, S., Lindqvist, D., Samuelsson, M., Lundberg, K., Postolache, T. T., Träskman-Bendz, L., Guillemin, G. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.248 · Cited by 345
Familial Transmission of Suicidal Behavior
Brent, D. A., & Melhem, N. (2008) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2008.02.001 · Cited by 329 · cited 1×
“Suicide risk is elevated in a wide range of diagnostic groups [23] and exhibits unique genetic variance that can be inherited separately from mood disorder risk [24].”
Ibrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309 · cited 1×
“For instance, the hypothesis that response to an initial infusion with ketamine could be prolonged by prescribing a similar glutamatergic agent in pill form (riluzole) was tested in TRD samples; however, riluzole showed no efficacy in these trials [31, 32].”
Cytokine levels in the blood may distinguish suicide attempters from depressed patients
Janelidze, S., Mattei, D., Westrin, Å., Träskman-Bendz, L., & Brundin, L. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2010.10.010 · Cited by 298 · cited 1×
“Together with a larger literature suggesting elevated pro-inflammatory and inflammatory cytokines in individuals at risk of suicide [37], these abnormalities within the kynurenine pathway suggest a state of immune activation and NMDA receptor stimulation that is posited to confer suicide risk.”
Ballard, E. D., Ionescu, D. F., Vande Voort, J. L., Niciu, M. J., Richards, E. M., Luckenbaugh, D. A., Brutsché, N. E., Ameli, R., Furey, M. L., & Zarate, C. A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.027 · Cited by 286
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.017 · Cited by 283 · cited 1×
“Notably, dissociative symptoms have been reported to correlate with the antidepressant effects of ketamine [40], suggesting a possible dichotomy between antidepressant and anti-suicide mechanisms.”
Therapeutic infusions of ketamine: do the psychoactive effects matter?
Dakwar, E., Anerella, C., Hart, C. L., Levin, F. R., Mathew, S. J., & Nunes, E. V. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.12.019 · Cited by 123
Cited by
Ketamine use in current clinical practice
Gao, M., Rejaei, D., & Liu, H. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.5 · Cited by 286
Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review
Molero, P., Ramos-Quiroga, J. A., Martin-Santos, R., Calvo-Sánchez, E., Gutiérrez-Rojas, L., & Meana, J. J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0519-3 · Cited by 280
Role of Inflammation in Suicide: From Mechanisms to Treatment
Brundin, L., Bryleva, E. Y., & Thirtamara Rajamani, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.116 · Cited by 257
“Several clinical trials have found that ketamine robustly decreases depressive and suicidal symptoms in as little as 40 min with effects lasting for several weeks (DiazGranados et al , 2010; Larkin and Beautrais, 2011; Price and Mathew, 2015; Price et al , 2009; Zarate et al , 2012).”
Kynurenine pathway metabolites and suicidality
Bryleva, E. Y., & Brundin, L. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.01.034 · Cited by 168
“Later clinical studies assessing the effect of ketamine on depression and suicidal behavior have confirmed the beneficial effects (Price and Mathew, 2015).”
Fan, W., Yang, H., Sun, Y., Zhang, J., Li, G., Zheng, Y., & Liu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.13743 · Cited by 87
Metadata
- Authors
- Price, R. B., & Mathew, S. J.
- Venue
- CNS Drugs
- Published
- 2015-02-26
- Volume
- 29
- Issue
- 3
- Pages
- 181-188
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2057360675
- Cited by
- 49
- References
- 23
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.